Notably, EDV nanocells charged with an miR-16 mimic and targeted to EGFR-expressing cancer cells with a bispecific antibody have entered a phase I clinical trial (NCT02369198) in patients with recurrent mesothelioma and NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.